Tirzepatide is a glucose-dependent insulinotropic polypeptide (GIP) receptor and glucagon-like peptide-1 (GLP-1) receptor agonist prescribed for weight management (in conjunction with a reduced calorie diet and exercise) in adults with obesity or who are overweight with at least one weight-related medical condition (such as high blood pressure, type 2 diabetes, obstructive sleep apnea, or cardiovascular disease)
You wont be able to file for both the standard deduction and itemized deductions, though
Get Personalized Treatment Wegovy starts at $1672 Once-weekly semaglutide injections in convenient, auto-injector pens
van Can, J
Wegovy, a higher-dose version of semaglutide, received FDA approval in 2021 for weight management in obese or overweight adults with certain medical conditions
The 0.25 mg dose is an initial titration dose designed to improve tolerability, not for glycaemic control, and elimination time is identical across all doses